Adjuvant Treatment with nivolumab in the Prevention of recurrence after curative treatment of Hepatocellular Carcinoma(NIVOLVE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jan 2022 Status changed from recruiting to completed.
22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
08 Jun 2021 Results assessing the efficacy and safety of nivolumab as an adjuvant therapy for hepatocellular carcinoma, and to identify biomarkers predictive of recurrence in patients after surgical resection or radiofrequency ablation, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com